SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

26 May 2022 Evaluate
The company witnessed a 10.32% growth in the revenue at Rs. 2319.63 millions for the quarter ended March 2022 as compared to Rs. 2102.57 millions during the year-ago period.Profit for the quarter ended March 2022 grew by 2.59% to Rs. 279.84 millions from Rs. 272.78 millions.The Operating Profit of the company witnessed a decrease to 416.45 millions from 429.62 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 2319.63 2102.57 10.32 8056.00 8135.63 -0.98 8056.00 8135.63 -0.98
Other Income 36.84 25.53 44.30 147.58 128.41 14.93 147.58 128.41 14.93
PBIDT 416.45 429.62 -3.07 1009.33 1483.12 -31.95 1009.33 1483.12 -31.95
Interest 2.07 2.82 -26.60 9.47 10.93 -13.36 9.47 10.93 -13.36
PBDT 414.38 426.80 -2.91 999.86 1472.19 -32.08 999.86 1472.19 -32.08
Depreciation 44.07 58.42 -24.56 169.49 201.26 -15.79 169.49 201.26 -15.79
PBT 370.31 368.38 0.52 830.37 1270.93 -34.66 830.37 1270.93 -34.66
TAX 90.47 95.60 -5.37 214.43 337.90 -36.54 214.43 337.90 -36.54
Deferred Tax -1.67 10.11 -116.52 -11.86 -10.38 14.26 -11.86 -10.38 14.26
PAT 279.84 272.78 2.59 615.94 933.03 -33.98 615.94 933.03 -33.98
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 17.95 20.43 -12.14 12.53 18.23 -31.27 12.53 18.23 -31.27

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×